SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-005035
Filing Date
2022-01-10
Accepted
2022-01-10 07:05:32
Documents
14
Period of Report
2022-01-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d200840d8k.htm   iXBRL 8-K 38513
2 EX-99.1 d200840dex991.htm EX-99.1 36018
6 GRAPHIC g200840g0109225955613.jpg GRAPHIC 2620
  Complete submission text file 0001193125-22-005035.txt   214711

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA epzm-20220110.xsd EX-101.SCH 2888
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE epzm-20220110_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE epzm-20220110_pre.xml EX-101.PRE 11405
8 EXTRACTED XBRL INSTANCE DOCUMENT d200840d8k_htm.xml XML 3342
Mailing Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139 617-229-5872
Epizyme, Inc. (Filer) CIK: 0001571498 (see all company filings)

IRS No.: 261349956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35945 | Film No.: 22519651
SIC: 2834 Pharmaceutical Preparations